Project Grant R01AG090534
Award Date
5/1/25
Completion Date
1/31/30
Dollars Obligated
$759K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40526, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $794,341 to the University of Illinois to investigate the roles of cellular senescence and blood-brain barrier dysfunction in Alzheimer's disease development and progression. The key objectives are to understand how viral and bacterial infections can initiate blood-brain barrier impairment and increase inflammation, leading to accelerated Alzheimer's disease pathology. The research...
The National Institute on Aging awarded a $1,952,654 Project Grant to the University of Kentucky Research Foundation on February 1, 2022 under the Aging Research program (CFDA 93.866). The three-year grant will fund research to evaluate reduced blood-brain barrier water exchange as a potential early biomarker for vascular cognitive impairment and dementia. Specifically, the University of Kentucky will study 140 healthy older adults at baseline and follow-up to assess the relationship between...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $242,310 to Emory University to conduct research into the role of interneuron dysfunction and tau pathology in the early stages of Alzheimer's disease (AD). The key goals are to: 1) Determine how pathological tau affects the excitability of neurons, and 2) Investigate how suppression of parvalbumin-expressing interneurons influences the progression of pathological tau in excitatory neurons....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Chapman University provides $991,800.00 to conduct research on developing a blood-brain barrier (BBB) penetrating form of the protein erythropoietin (EPO) as a potential therapeutic for Alzheimer's disease (AD). The key objectives are to: Determine the optimal dose and therapeutic window for the BBB-penetrating EPO fusion protein (TFRMAB-EPO) in mouse models of AD. Assess the safety profile of chronic...
The National Institute on Aging (NIA) awarded a $7,249,563 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the Regents of the University of California, San Francisco (UCSF). This 3-year award, starting on Aug 1, 2023, will support research to characterize the structural properties and variability of tau protein aggregation in different brain cell types and at different disease stages of Alzheimer's and related dementias (ADRD). The project aims to develop new...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $1,003,116 will support research at the University of Alabama at Birmingham (UAB) to investigate synaptic resilience to tau protein accumulation in Alzheimer's disease. The goal is to identify protein targets and cellular pathways that can modulate tau seeding, tau-induced synaptic dysfunction, and synaptic preservation in the context of Alzheimer's pathology. This 2-year study aims to address...
This $408,638 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the effect of trans-synaptic spread of pathogenic tau protein from the entorhinal cortex to the hippocampus in Alzheimer's disease (AD) and other neurodegenerative conditions. The 2-year project at Virginia Commonwealth University will use adeno-associated viral vectors, immunofluorescence, and cellular electrophysiology to monitor tau spread and assess its...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $799,700 to the University College London (UCL) to conduct systems genetics analysis of resilience to tauopathy in Alzheimer's disease and related dementias. The project aims to combine a mouse model of tauopathy with the genetically diverse BXD mouse population to identify genetic factors underlying resilience to tau pathology, which may represent novel therapeutic targets. This 5-year study,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $757,027 to the University of Washington to conduct research on the mechanisms underlying the synergistic relationship between tau and TDP-43 proteins in Alzheimer's disease (AD). The 5-year project, starting January 1, 2025, aims to investigate how the combination of tau and TDP-43 pathologies impairs the lysosomal autophagy pathway, which is a compensatory mechanism observed in AD. The...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Arizona State University provides $431,750 in funding to conduct research on the role of tau protein proteolysis in Alzheimer's disease. The key objectives are to: 1) test and rank the ability of tau protein peptide fragments generated by proteolysis to induce the aggregation of full-length tau protein, and 2) characterize the intracellular signaling activity of these tau peptides. Using...